Abstract
The purpose of this study was to evaluate the effect of pH on the dissolution behavior of metaxalone in the marketed product Skelaxin tablets. The dissolution was evaluated using United States Pharmacopeia (USP) dissolution Apparatus 2 and 3 at pHs ranging from 1.5 to 7.4 Results from these studies show that the dissolution of this product is pH dependent. At low pH (simulated gastric fluid, pH 1.5), the dissolution of metaxalone from Skelaxin tablets, was less than 10% over 75 minutes; whereas, dissolution at pH 4.5 showed greater than 90% release in the same time period. These results were consistent for both Apparatus 2 and 3. This suggests that Skelaxin Tablets should be considered a delayed release dosage form.
KeyWords: Metaxalone, dissolution, pH dependence, apparatus 3
Full Text
The Full Text of this article is available as a PDF (219.1 KB).
References
- 1.Bruce RB, Turnbull L, Newman J, Pitts J. Metabolism of metaxalone. J Med Chem. 1966;9(3):286–288. doi: 10.1021/jm00321a004. [DOI] [PubMed] [Google Scholar]
- 2.Harden RN, Argoff C. A review of three commonly prescribed skeletal muscle relaxants. J Back Musculoskeletal Rehabil. 2000;15(2–3):63–66. doi: 10.3233/bmr-2000-152-303. [DOI] [PubMed] [Google Scholar]
- 3.Pfeifer MA, Ross DR, Schrage JP, Gelber DA, Schumer MP, Crain GM, Markwell SS, Jung S. A highly successful and novel model for the treatment of chronic painful diabetic neuropathy. Diabetes Care. 1993;16(8):1103–1115. doi: 10.2337/diacare.16.8.1103. [DOI] [PubMed] [Google Scholar]
- 4.Spierings EL. Chronic daily headache: a review. Headache Quarterly. 2000;11(3):181–196. [Google Scholar]
- 5.Ward TN. Providing relief from headache: current options for acute and prophylactic treatment. Postgrad Med. 2000;108(3):121–128. doi: 10.3810/pgm.2000.09.1.1209. [DOI] [PubMed] [Google Scholar]
- 6.Rxlist 2002. Metaxalone Monograph. Available at: http://www.rxlist.com.Accessed April 2001.
- 7.Saife M, Shah, J, inventors; Assigned to Elan Pharmaceuticals, Inc, Method for increasing the bioavailability of metaxalone. US patent 6 407 128 B1. June 18, 2002.
- 8.American Society of Health-System Pharmacists.AHFS Drug Information 2001. Bethesda, MD: American Society of Health-System Phamacists; 2001.